8-K: Pulse Biosciences Q3 2025: Revenue Growth Amid Rising Losses

Pulse Biosciences reported initial revenue of $86 thousand in Q3 2025 from its nPulse Vybrance system, alongside increased GAAP and non-GAAP net losses and higher operating expenses as it advances clinical trials and commercialization efforts.

Summary

• Generated initial product revenue of $86 thousand in Q3 2025 from the limited market release of the nPulse Vybrance percutaneous electrode system for benign thyroid nodules.
• Initiated the PRECISE-BTN multi-center clinical study for benign thyroid nodules, with 40% of subjects already enrolled.
• Treated over 200 patients to date across pilot programs, the PRECISE-BTN Study, and initial commercial procedures for soft tissue ablation.
• Received FDA IDE approval and enrolled the initial subject in the NANOCLAMP AF study for surgical atrial fibrillation ablation, marking the first FDA-approved PFA study for a surgical cardiac ablation device in concomitant procedures.
• Treated 44 patients in Europe for surgical AF ablation feasibility study, showing positive clinical outcomes including durable and consistent pulmonary vein and posterior box isolation with rapid ablation times.
• Submitted FDA IDE application for the nPulse 360 catheter for endocardial AF ablation, with plans to commence a pivotal study in Q1 2026.
• Treated 150 patients with the nsPFA 360 catheter in a multi-center AF feasibility study in Europe.
• GAAP net loss for Q3 2025 was ($19.4) million, an increase from ($12.7) million in Q3 2024.
• Non-GAAP net loss for Q3 2025 was ($13.5) million, up from ($9.4) million in Q3 2024.
• Total GAAP costs and expenses rose to $20.5 million in Q3 2025 from $13.7 million in Q3 2024, driven by organizational expansion, clinical trials, commercialization, and stock-based compensation.
• Cash and cash equivalents stood at $95.2 million as of September 30, 2025, down from $106.3 million at June 30, 2025.
• Cash used in operating activities increased to $13.0 million in Q3 2025 from $9.0 million in Q3 2024.

Sentiment

Score: 6

Explanation: While financial losses increased and cash burn accelerated, the company achieved significant clinical and regulatory milestones, including initial revenue generation, FDA IDE approval for a novel surgical AF ablation device, and progress in multiple clinical studies. The positive early clinical data is encouraging, but the increasing operational costs and net losses indicate continued investment in R&D and commercialization without immediate profitability.

Positives

• Achieved initial product revenue of $86 thousand in Q3 2025, indicating early commercialization progress.
• Successfully initiated and enrolled 40% of subjects in the PRECISE-BTN clinical study for benign thyroid nodules.
• Received FDA IDE approval for the NANOCLAMP AF study, a significant regulatory milestone for surgical cardiac ablation, representing the first PFA study approved by FDA for this application.
• Reported positive clinical outcomes from the European feasibility study for surgical AF ablation, demonstrating durable and consistent pulmonary vein and posterior box isolation with rapid ablation times in 44 patients.
• Submitted FDA IDE application for the nPulse 360 catheter, progressing towards a pivotal study in Q1 2026.
• Treated a total of 150 patients with the nsPFA 360 catheter in the European AF feasibility study.
• Cash and cash equivalents of $95.2 million as of September 30, 2025, provide runway for ongoing operations.

Negatives

• GAAP net loss increased to ($19.4) million in Q3 2025 from ($12.7) million in Q3 2024.
• Non-GAAP net loss increased to ($13.5) million in Q3 2025 from ($9.4) million in Q3 2024.
• Total GAAP costs and expenses increased significantly to $20.5 million in Q3 2025 from $13.7 million in Q3 2024.
• Cash and cash equivalents decreased to $95.2 million as of September 30, 2025, from $106.3 million as of June 30, 2025.
• Cash used in operating activities increased to $13.0 million in Q3 2025 from $9.0 million in Q3 2024, indicating higher cash burn.
• Accumulated deficit increased to ($445.8) million as of September 30, 2025, from ($390.5) million as of December 31, 2024.

Risks

• The effectiveness of the nPulse technology to non-thermally clear cells while sparing adjacent noncellular tissue may not be as expected.
• Potential market opportunities for the use of nsPFA to treat atrial fibrillation or benign thyroid nodules may not grow as anticipated.
• Early clinical successes may not be predictive of the safety and effectiveness of any medical device, such as the nPulse Cardiac Surgical System.
• Future clinical and regulatory initiatives, including FDA IDE approval for presently pending submissions, may not be successful or timely.
• The nsPFA technology may not become a disruptive, superior, and durable treatment option for atrial fibrillation or any other medical condition.
• Actual results may differ materially from forward-looking statements due to known and unknown risks, uncertainties, and assumptions, some beyond the company's control.

Future Outlook

Pulse Biosciences plans to commence an FDA IDE study for its nPulse 360 catheter for endocardial AF ablation in Q1 2026. The company continues to advance its nPulse technology platform, aiming to validate its safety, efficacy, and market-disrupting potential across its three market programs. Management expects to continue accomplishing clinical and regulatory milestones to deliver the benefits of nanosecond PFA to more patients and providers.

Management Comments

• "We continue to accomplish the clinical and regulatory milestones required to deliver the benefits of nanosecond PFA to more patients and providers."
• "We are advancing early market adoption for the nPulse Vybrance Percutaneous Electrode System, enrolling patients in the IDE pivotal study for the nPulse Cardiac Surgery System and progressing our IDE submission for our nPulse 360 Catheter, while we continue to treat patients in our two feasibility studies in Europe."
• "The Pulse Biosciences team is executing our strategy to validate the safety, efficacy, and market-disrupting potential of our nPulse technology platform and we are very pleased with the patient outcomes and our early clinical results achieved to date."

Industry Context

Pulse Biosciences operates in the rapidly evolving bioelectric medicine and medical device industry, specifically targeting ablation procedures for conditions like atrial fibrillation and benign thyroid nodules. Its novel nanosecond Pulsed Field Ablation (nsPFA) technology aims to offer a non-thermal cell clearing method, potentially differentiating it from traditional thermal ablation techniques. The FDA IDE approval for a surgical cardiac ablation device using PFA highlights a significant regulatory step for this technology in the U.S. market, positioning Pulse Biosciences as a potential innovator in a competitive space dominated by established players using radiofrequency or cryoablation. The focus on both percutaneous and surgical applications suggests a broad strategy to capture market share across different procedural settings.

Comparison to Industry Standards

• The FDA IDE approval for the NANOCLAMP AF study represents the first PFA study approved by FDA for a surgical cardiac ablation device in concomitant surgical procedures, indicating a pioneering position in this specific application compared to existing thermal ablation technologies.
• The positive clinical outcomes from the European feasibility study for surgical AF ablation, showing durable and consistent pulmonary vein isolation and posterior box isolation with rapid ablation times in 44 patients, suggest competitive efficacy and procedural efficiency against current industry standards for AF ablation, such as radiofrequency or cryoablation, which often face challenges with durability and procedure time.
• The company's nsPFA technology, designed to non-thermally clear cells while sparing adjacent noncellular tissue, aims to offer a safety profile advantage over thermal ablation methods, which can carry risks of collateral tissue damage. This differentiates it from thermal ablation devices used by competitors like Medtronic (e.g., Arctic Front Advance Cryoablation Catheter) or Johnson & Johnson (e.g., Carto 3 System with Thermocool SmartTouch Catheter).

Stakeholder Impact

• Shareholders: Increased net losses and cash burn may concern investors, but significant clinical and regulatory progress, along with initial revenue, could provide long-term value potential. The decrease in cash from the previous quarter indicates continued capital deployment for growth.
• Patients: The advancement of nPulse technology in clinical trials for benign thyroid nodules and atrial fibrillation offers potential new, non-thermal treatment options, potentially improving quality of life.
• Providers (Doctors/Hospitals): The nPulse Vybrance and Cardiac Surgery Systems offer new tools for soft tissue and cardiac ablation, potentially providing safer and more effective procedures with rapid ablation times.
• Employees: The expanding organization mentioned as a driver for increased administrative expenses suggests continued growth and hiring.

Next Steps

• Continue enrollment in the PRECISE-BTN multi-center clinical study for benign thyroid nodules.
• Continue enrollment in the NANOCLAMP AF study for surgical atrial fibrillation ablation.
• Commence an FDA IDE pivotal study for the nPulse 360 catheter for endocardial AF ablation in Q1 2026.
• Continue treating patients in the two European feasibility studies for AF ablation.
• Advance early market adoption for the nPulse Vybrance Percutaneous Electrode System.
• Execute strategy to validate the safety, efficacy, and market-disrupting potential of the nPulse technology platform.

Key Dates

Recommendation

While Pulse Biosciences reported increased net losses and cash burn, these are largely attributable to significant investments in clinical trials, regulatory approvals, and early commercialization efforts for its novel nsPFA technology. The company achieved critical milestones, including initial revenue generation, FDA IDE approval for a surgical AF ablation study, and positive early clinical data. These operational advancements are crucial for long-term value creation in the medical device sector. However, the increased losses and cash usage warrant a cautious approach. The stock is a "hold" as the company is in a high-growth, high-investment phase, with promising technology but not yet demonstrating profitability or a clear path to sustained positive cash flow. Investors should monitor future clinical trial results, regulatory approvals, and the pace of commercial adoption.

Keywords

Pulse Biosciences, PLSE, Nanosecond Pulsed Field Ablation, nsPFA, nPulse technology, Atrial Fibrillation, AF ablation, Benign Thyroid Nodules, Soft Tissue Ablation, Medical Device, Clinical Trials, FDA IDE, Cardiac Surgery System, Vybrance, 360 Catheter, Bioelectric Medicine